AstraZeneca and Banner Alzheimer's Institute, collaboration to evaluate new tool targeting Alzheimer's disease

December 19, 2007 — The Banner Alzheimer’s Institute and AstraZeneca (NYSE:AZN) announced that they will collaborate to help advance understanding of Alzheimer’s disease and increase knowledge of potential new avenues for treatment through the use of cutting-edge brain imaging methods. The new alliance will focus on the evaluation and further development of a radioligand discovered by AstraZeneca. This radioligand is a molecule that binds to amyloid plaque — protein deposits in the brain that are a hallmark of Alzheimer’s disease — and allows the plaque to be measured in real time using a positron emission tomography (PET) scan... The Banner Alzheimer’s Institute's Press Release -